Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 146

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 146
---

Sub merged with and into Legacy NewGenIvf, resulting in Legacy NewGenIvf being a wholly-owned subsidiary of the Company (such second step
in isolation, the “Acquisition Merger”). The surviving entity of the Business Combination, together with its subsidiaries
is referred to in this prospectus as “NewGenIvf,” the “Company,” “we,” “our,” or “us,”
unless the context otherwise requires.

On June 12, 2023, the
parties to the Merger Agreement entered into the First Amendment to Merger Agreement (the “First Amendment”), pursuant to
which Legacy NewGenIvf agreed to provide non-interest bearing loans in an aggregate principal amount of up to $560,000 (the “Loan”)
to ASCA to fund any amount that would be required in order to further extend the period of time available for ASCA to consummate a business
combination and for ASCA’s working capital, payment of professional, administrative and operational fees and expenses, and other
purposes as mutually agreed by ASCA and Legacy NewGenIvf. Such loans were to become repayable upon the closing of the Acquisition Merger.
In addition, pursuant to the First Amendment, subject to receipt of at least $140,000 as part of the Loan from NewGenIvf, ASCA agreed
to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf’s failure to deliver audited financial
statements by no later than February 28, 2023.

On December 6, 2023, the parties
to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the “Second Amendment”) which amended and
modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf’s board of directors following the consummation
of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3)
of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the
conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in
connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately
after the consum